A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
At a glance
- Drugs GSK 2646264 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2018 Status changed from active, no longer recruiting to completed.
- 06 Aug 2018 Planned End Date changed from 31 Jul 2018 to 8 Aug 2018.